Immunotherapy targeting survivin for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial tests an experimental immunotherapy made from your own immune cells, designed to train them to attack a protein (survivin) found in glioblastoma. It is a phase 1 study, meaning it is one of the first times this treatment is being tested in people, and it is given alongside standard radiation and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been newly diagnosed with glioblastoma (grade 4 brain cancer).
- You must be 18 to 70 years old.
- You should be up and about, able to care for yourself, and do most daily activities.
- Your tumor must test positive for a protein called survivin, which this therapy targets.
- You must agree to receive only standard therapy (radiation and temozolomide) plus this immunotherapy during the trial.
- You must have adequate blood counts and liver/kidney function, and be able to have MRI scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own immune cells that targets a protein (survivin) found on your tumor. It is given alongside the standard radiation and chemotherapy to see if it helps fight the cancer.
This trial tests an experimental 'vaccine' made from your own immune cells (dendritic cells). The vaccine is designed to train your immune system to attack the brain tumor. It is for people whose glioblastoma has returned or progressed after standard treatment.
This trial tests a vaccine made from your own immune cells to fight glioblastoma, a type of brain cancer. It may help your body attack the cancer more effectively after standard treatments.
This trial tests a personalized vaccine (made from your own cells) combined with a common chemotherapy drug, temozolomide, for people with newly diagnosed glioblastoma. The goal is to train your immune system to fight the tumor and hopefully slow its growth.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial is testing a new vaccine (Bvax) added to the usual chemotherapy and radiation for glioblastoma. It aims to train your immune system to fight the tumor and possibly improve outcomes.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.